• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunocore Holdings Plc ADR (NQ: IMCR )

    35.93 +0.81 (+2.31%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 999,464
    Open 35.49
    Bid (Size) 14.28 (2)
    Ask (Size) 36.99 (1)
    Prev. Close 35.12
    Today's Range 35.02 - 36.02
    52wk Range 35.02 - 76.98
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
    From Immunocore Holdings plc
    Via GlobeNewswire
    Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga

    Performance

    YTD
    -49.85%
    -49.85%
    1 Month
    -25.11%
    -25.11%
    3 Month
    -42.53%
    -42.53%
    6 Month
    -47.19%
    -47.19%
    1 Year
    -39.69%
    -39.69%

    More News

    Read More
    Analyst Expectations For Immunocore Hldgs's Future
    Via Benzinga
    Where Immunocore Hldgs Stands With Analysts
    Via Benzinga
    Immunocore Hldgs Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
    Via Benzinga
    Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore to present at the Jefferies Global Healthcare Conference
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
    From Immunocore Holdings plc
    Via GlobeNewswire
    Key Takeaways From Immunocore Hldgs Analyst Ratings
    Via Benzinga
    Immunocore Hldgs's Earnings: A Preview
    Via Benzinga
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    IMCR Stock Earnings: Immunocore Hldgs Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Immunocore reports first quarter financial results and provides a business update
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore announces upcoming presentation and posters at ASCO 2024
    From Immunocore Holdings plc
    Via GlobeNewswire
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio
    Via InvestorPlace
    Immunocore presented two posters at CROI 2024
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore to present at upcoming investor conferences
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore Prices Upsized Convertible Senior Notes Offering
    From Immunocore Holdings Limited
    Via GlobeNewswire
    Immunocore Announces Proposed Convertible Senior Notes Offering
    From Immunocore Holdings Limited
    Via GlobeNewswire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.